The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 351:2773-2774 December 23, 2004 Number 26
NextNext

Estrogen Receptor {beta} in Prostate Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: In the Prostate Cancer Prevention Trial,1 more than 18,000 healthy volunteers were randomly assigned to receive either finasteride (5 mg daily) or placebo. The incidence of prostate cancer in the finasteride group was 18.4 percent, as compared with 24.4 percent in the placebo group. A bigger surprise was that the incidence of tumors with a Gleason grade of 7, 8, 9, or 10 was higher in the finasteride group than in the placebo group (37.0 percent vs. 22.2 percent, P<0.001), meaning that there were more cases of aggressive cancer with finasteride than there were with placebo.1

We . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.